Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATV/RTV plus 3TC versus ATV/RTV plus TDF/FTC in treatment-naive HIV-1-infected subjects
2011-006187-47Phase 3Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Human immunodeficiency virus infection type 1 comparing ATV/RTV plus 3TC with ATV/RTV plus TDF/FTC (2 arms). Primary endpoint: Week 48 virologic suppression < 40 copies/mL. Started Nov 2012; status: terminated.
02
Drugs
atazanavirritonavirlamivudinetenofovir disoproxil fumarateemtricitabine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2011-006187-47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006187-47.